ArticleAmerican journal of respiratory cell and molecular biology2019
Proline-Glycine-Proline Peptides Are Critical in the Development of Smoke-induced Emphysema.
Article in American journal of respiratory cell and molecular biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Matrikines dictate the amplitude of inflammation in smoke-related Streptococcus pneumoniae pulmonary infection.JCI insight · 2026Article
- Targeting the proline-glycine-proline-protease feed-forward loop attenuates primary graft dysfunction after lung transplantation.Frontiers in immunology · 2026Article
- Neutrophil Plasticity in Airway Disease: Balancing Damage and Repair.Journal of innate immunity · 2026Review
- A lactobacilli-based inhaled live biotherapeutic product attenuates pulmonary neutrophilic inflammation.Nature communications · 2024Article
- Gut Microbiome and Transcriptomic Changes in Cigarette Smoke-Exposed Mice Compared to COPD and CD Patient Datasets.International journal of molecular sciences · 2024Article
- Neutrophil elastase activates the release of extracellular traps from COPD blood monocyte-derived macrophages.Clinical and translational science · 2023Article
- Advances in metabolomics of chronic obstructive pulmonary disease.Chinese medical journal pulmonary and critical care medicine · 2023Review
- LC-MS/MS method for proline-glycine-proline and acetylated proline-glycine-proline in human plasma.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2023Article
- Contribution of adaptive immunity to human COPD and experimental models of emphysema.Physiological reviews · 2023Review
- Efficacy of a Probiotic and Herbal Supplement in Models of Lung Inflammation.Microorganisms · 2022Article
- Effects of Cigarette Smoke on Adipose and Skeletal Muscle Tissue: In Vivo and In Vitro Studies.Cells · 2022Article
- Changes in intestinal homeostasis and immunity in a cigarette smoke- and LPS-induced murine model for COPD: the lung-gut axis.American journal of physiology. Lung cellular and molecular physiology · 2022Article
- Corticotropin releasing hormone as an identifier of bronchiolitis obliterans syndrome.Scientific reports · 2022Article
- Update in Chronic Obstructive Pulmonary Disease 2019.American journal of respiratory and critical care medicine · 2020Review
- Taming Peptides with Peptides: Neutralizing Proline-Glycine-Proline with l-Arginine-Threonine-Arginine to Treat Cigarette Smoke-induced Emphysema.American journal of respiratory cell and molecular biology · 2019Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
Chronic obstructive pulmonary disease (COPD) is a major cause of mortality worldwide and is characterized by an excessive airway neutrophilic response. The neutrophil chemoattractant proline-glycine-proline (PGP) and its more potent acetylated form (acPGP) have been found to be elevated in patients with COPD and act via CXCR2. Here, we investigated the impact of neutralizing PGP peptides in a murine model for emphysema. The PGP-neutralizing peptide l-arginine-threonine-arginine (RTR) was used first in a 6-week model of cigarette smoke exposure, where it attenuated lung inflammation. Then, in a model of chronic smoke exposure, mice were exposed to cigarette smoke and RTR treatment was initiated after 10 weeks of smoke exposure. This treatment was continued together with smoke exposure for another 13 weeks, for a total of 23 weeks of smoke exposure. RTR significantly inhibited neutrophil and macrophage influx into the lungs in the 6-week model of exposure. RTR also attenuated the development of emphysema, normalized lung volumes, and reduced right ventricular hypertrophy in the chronic exposure model. Murine epithelia expressed CXCR2, and this expression was increased after smoke exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.